Maggie Bobbin

Maggie L. Bobbin, Ph.D., is the Director of Assay Development, NGS, Off-Target, and Bioanalysis at Mammoth Biosciences. She leads the technical strategy for genomic safety and bioanalytical characterization across the company’s CRISPR-based therapeutic pipeline. With over ten years of expertise in genome editing, Dr. Bobbin serves as a primary technical lead for regulatory interactions. She specializes in addressing complex requirements for nuclease specificity, structural variation assessment, and genomic integrity. Her team implements advanced Next-Generation Sequencing (NGS) pipelines for off-target discovery and verification, alongside bioanalytical tools to characterize biodistribution.